Business
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim
Ruling preserves current contracted royalty rates and rejects Tesaro’s request for any royalty reductionTrial to adjudicate Anaptys’ contract claims and right to seek reversion of Jemperli against Tesaro/GSK is scheduled for July 14-17, 2026 SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that the Delaware Chancery Court has dismissed Tesaro’
About this update from Anaptysbio, Inc.
[{"type":"image","alt":"AnaptysBio, Inc.","displaySize":"","headline":null,"caption":"AnaptysBio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/5dd7f30a0ad6f5e52c819b2cf00b5a83"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.iih9fgXNbOAwMH5sv5aNg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOQ--/https://media.zenfs.com/en/globenewswire.com/5dd7f30a0ad6f5e52c819b2cf00b5a83","width":300,"height":85}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Ruling preserves current contracted royalty rates and rejects Tesaro’s request for any royalty reduction","length":104,"tagName":"p"}]},{"val":[{"type":"text","content":"Trial to adjudicate Anaptys’ contract claims and right to seek reversion of Jemperli against Tesaro/GSK is scheduled for July 14-17, 2026","length":137,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":241,"olType":false},{"type":"text","content":"SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that the Delaware Chancery Court has dismissed Tesaro’s anticipatory breach of contract claim against Anaptys. The ruling agrees with Anaptys’ position that it has never repudiated the Collaboration and Exclusive License Agreement (“Collaboration Agreement”) with Tesaro, a subsidiary of GSK, governing the development and commercialization of Jemperli.","length":557,"tagName":"p"},{"type":"text","content":"As stated in Anaptys’ original filing, the company’s motion explained “why, as a matter of law, Anaptys has never repudiated the Collaboration Agreement and how Anaptys has only sought to vindicate its contract rights.” The Court’s decision confirms that Tesaro’s anticipatory breach of contract claim was insufficiently pleaded and rejects Tesaro’s request for any royalty reduction.","length":384,"tagName":"p"},{"type":"text","content":"“The Court’s decision affirms what we have maintained from the beginning: Tesaro’s anticipatory breach claim was baseless, and this ruling is an important validation of our efforts to protect our contractual rights to the Jemperli royalty stream for our shareholders,” said Dan Faga, president and chief executive officer of Anaptys. “We are...